There was a notable decrease in common ophthalmic procedures among Medicare beneficiaries during the first year of the COVID-19 pandemic, according to a study published Feb. 6 in JAMA Ophthalmology.

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be pr ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month ...

In this Healio Video Perspective from Telling It Like It Is, Andrew G. Lee, MD, explains why a team approach is needed for neuro-ophthalmic conditions.

Glenmark Pharmaceuticals and FDC Ltd are recalling some products in the US market. Glenmark is recalling certain strengths of ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

Clear Channel Outdoor Holdings, Inc., (NYSE:CCO) announced today that Scott Wells, Chief Executive Officer of Clear Channel ...

New Delhi: Glenmark Pharmaceuticals on Friday said its subsidiary has launched generic medication to treat glaucoma in the US ...

Glenmark Pharma introduces generic Xalatan ophthalmic solution, 0.005% in US: Our Bureau, Mumbai Friday, February 14, 2025, 12:15 Hrs [IST] Glenmark Pharmaceuticals Inc., USA (Gle ...

Glenmark launches Latanoprost Ophthalmic Solution, targeting $113.5 million market, showcasing commitment to quality eye care ...

Glenmark Pharmaceuticals (NSE: GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% ...